PTC Therapeutics
Biotech
South Plainfield, NJ

Overall Rank: 34
Category: Biotechnology
Category Rank: 17

Awards:

  • Top HealthTech Company of 2023

Profile

Founded in 1998, PTC is a global commercial, diversified biopharmaceutical company. Their team is deeply committed to a unifying purpose: Extending life’s moments for rare disease patients and their loved ones.


As a science-driven, global biopharmaceutical company, they combine their strong clinical and scientific expertise with dedication to using groundbreaking science and new technologies to find innovative ways to treat these diseases, which can give patients and their families more moments.


Visit: www.ptcbio.com


Become a Premium Subscriber

Please purchase a premium subscription to continue reading this report.

Subscribe Now

Key Products

Genetic Disorders


A genetic disorder is an illness caused by abnormalities known as mutations in genes or chromosomes. Most genetic disorders are quite rare and affect one person in every several thousands or millions. We are committed to discovering and developing therapeutics for patients living with genetic disorders.


Oncology


PTC is developing innovative cancer treatments involving enzyme and protein inhibition therapies.


Virology


PTC wanted to part of the solution to help the world develop treatments to address the COVID-19 pandemic and looked within its pipeline to determine whether it had potential therapies to treat COVID-19 patients.


EMFLAZA® (deflazacort) is approved in the US for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older.


Key Executives

Stuart W. Peltz, Ph.D., Founder and Chief Executive Officer


Stuart W. Peltz, Ph.D. – Founder and Chief Executive OfficerStuart W. Peltz, Ph.D. founded PTC Therapeutics in 1998 and has served as chief executive officer and a member of the board of directors since the company’s inception.


Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders.


Before founding PTC, Stu was in academia, working as a professor in the department of molecular genetics and microbiology at the Robert Wood Johnson Medical School at, Rutgers University.


Stu is a recognized scientific leader in RNA biology and post-transcriptional control processes involving mRNA turnover and translation. He has amassed more than 30 years of research and more than 100 publications to his credit in this area.


In addition, Stu has received several business and scientific awards. Notably, he was elected as a fellow of the American Academy for the Advancement of Science in 2010. In 2009, he was recognized as one of PharmaVoice’s “100 Most Inspiring People” and received the Dr. Sol J. Barer Award for Vision, Innovation and Leadership in 2014.


Stu earned a doctorate of philosophy from the McArdle Laboratory for Cancer Research at the University of Wisconsin.


Neil Almstead, Ph.D. | Chief Technical Operations Officer


Neil Almstead, Ph.D. – Chief Technical Operations OfficerWith a career spanning more than 20 years with PTC, Neil Almstead, Ph.D. has served in several executive positions since 2000. He initially came aboard as the company’s senior vice president, research and chemistry, manufacturing and controls. From there, he assumed the role of executive vice president, research, pharmaceutical operations and technology.


Today, Neil oversees the manufacturing and supply chain for the small-molecule and gene-therapy programs as PTC’s chief technical operations officer.


Before joining PTC, Neil spent six years working as a project manager at Procter & Gamble. Neil has co-authored more than 75 publications and patents in genetic disorders, oncology, and inflammatory diseases.


Neil earned his bachelor of science from Clarkson University and his doctorate of philosophy in organic chemistry from the University of Illinois at Urbana-Champaign. He completed his postdoctoral research at the University of Basel.


Mark E. Boulding, Executive Vice President and Chief Legal Officer


Mark E. Boulding – Executive Vice President and Chief Legal OfficerMark E. Boulding joined PTC in 2002 and has served as executive vice president and chief legal officer since March 2012. Mark was PTC’s senior vice president and general counsel from 2002 to 2012.


Prior to joining PTC, Mark was general counsel, executive vice president, and secretary with MedicaLogic/Medscape and a partner in two Washington, D.C.-based law firms. Before this, Mark represented clients on various corporate and litigation matters while working at a New York-based law firm.


Mark currently serves on the board of directors for the Amyotrophic Lateral Sclerosis Emergency Treatment Fund. He is also an active member of the American Association for the Advancement of Science and the Association of Corporate Counsel.


Mark earned his bachelor of arts from Yale University and his doctorate of jurisprudence from the University of Michigan.


Emily Hill, Chief Financial Officer


Emily Hill – Chief Financial OfficerEmily Hill joined PTC in November 2013 and has worked across the fields of investor relations and finance during her tenure. In her role as chief financial officer, Emily works with the executive committee to execute the company’s long-term financial and investor strategies. Before she became PTC’s CFO, Emily was senior vice president and head of investor relations.


Prior to joining PTC, Emily was director of investor relations at Warner Chilcott, where she was responsible for leading the entire investor relations operation. Additionally, Ms. Hill worked in investor relations at Genzyme Corporation. Prior to Genzyme, Emily got her start in the biotech industry by working as a biotech equity research associate at Summer Street Partners.


Emily has a master of business administration with a concentration in finance from Fordham Gabelli School of Business at Fordham University. She also holds a degree in pharmacology from Tufts University School of Biomedical Research and a bachelor of arts from Hamilton College.


Matthew B. Klein, MD, MS, FACS, Chief Operating Officer


Matthew B. Klein, MD, MS, FACS – Chief Operating OfficerMatthew B. Klein, M.D., M.S., FACS, is chief operating officer at PTC. Prior to joining PTC, Matt was chief executive and chief medical officer of BioElectron Technology Corporation, a biotechnology company focused on the development of redox-active small molecules for mitochondrial disease and related disorders of oxidative stress. He has also served as chief medical officer and senior vice president of Edison Pharmaceuticals.


Before joining BioElectron, Matt was the Auth-Washington Research Foundation chair of restorative burn surgery at the University of Washington.


Matt completed his bachelor’s degree in chemistry and history at the University of Pennsylvania where he graduated summa cum laude and Phi Beta Kappa. Matt earned his doctorate of medicine with honors from Yale University.


Eric Pauwels, Chief Business Officer


Eric Pauwels – Chief Business OfficerEric Pauwels joined PTC in March 2015 as Senior Vice President and General Manager of the Americas and became Chief Business Officer in 2020. In his role, Eric leads our customer-facing teams worldwide, commercial business operations, global medical affairs, and business development.


Eric brings more than 35 years of healthcare and the last 17 years focused specifically on rare diseases building global commercial organizations and with launches of 10 innovative therapies for lysosomal storage diseases, hereditary angioedema, short bowel syndrome, hypoparathyroidism, Duchenne muscular dystrophy, transthyretin-related amyloidosis (h-ATTR), familial chylomicronemia syndrome and other rare genetic disorders.


Prior to joining PTC, Eric was the Chief Commercial Officer and President of International for NPS Pharmaceuticals from 2011-2015. Prior to NPS Pharmaceuticals, Eric served as the first Chief Commercial Officer for Shire Human Genetic Therapies Rare Disease Business, following the acquisition of TKT from 2005-2010. Previously, Eric held the position of vice president of global strategic marketing for men’s health and cardiovascular diseases at Bayer Healthcare Pharmaceuticals and held general management positions in the USA, China, France, and Belgium for Fournier Pharma and Johnson & Johnson.


Eric earned his Bachelor of Science degree from California State Polytechnic University in Pomona, California.


Martin Rexroad, Chief Culture & Community Officer


Martin Rexroad – Chief Culture & Community OfficerMartin Rexroad draws from more than 25 years of human resources experience in his role as chief culture and community officer and formerly, as senior vice president, human resources. He joined PTC in 2013.


Prior to working at PTC, Martin served as vice president of human resources at both Terumo Medical Corporation and Osteotech, Inc. Additional leadership roles in Martin’s history include director, human resources development & technology at Altria Corporate Services, vice president human resources service center at New York Life Insurance Company and director, human resources division support – Northeast sales region .


Martin earned his bachelor of science in business management. He went on to earn his master of science in business administration with a focus on human resources and labor relations from Virginia Tech.


Ellen Welch, Ph.D., Chief Scientific Officer


Ellen Welch, Ph.D. – Chief Scientific OfficerEllen Welch, Ph.D., currently serves as the chief scientific officer at PTC. Ellen has applied her understanding of post-transcriptional control mechanisms to the discovery and development of small molecule therapeutics that modulate RNA-mediated processes.


Over the last 20 years, she has been involved in the discovery and development of small molecules that promote the readthrough of nonsense codons and in the identification of small molecules that modulate splicing. The application of these mechanisms and others are the focus of her ongoing efforts to bring therapies to patients with rare disorders.


Ellen earned her doctorate of philosophy in molecular biology from the University of Massachusetts Medical School and completed her postdoctoral studies in molecular biology at Robert Wood Johnson Medical School at Rutgers University.


Company Responsibility

The Environment


As a science-based company, we understand the impact people have on the environment. They care about our world and have a stead-fast commitment to maintaining the environment. They have always ensured our actions were compliant with environmental requirements and regulations and have encouraged employee actions which are environmentally-friendly.



  • Their laboratories meet all environmental standards and have consistently passed inspections by multiple government authorities

  • They have installed charging stations for electric vehicles at our corporate headquarters

  • They have replaced light bulbs in all buildings at our corporate headquarters with LED lighting

  • They have utilized innovative scientific approaches to reduce a generation of radioactive waste

  • They have a strong company wide recycling program and seek to maximize our use of recycled materials

  • They have filtered water coolers in all facilities to encourage the use of tap water in lieu of bottled water

  • They encourage our employees to use reusable water bottles, cups, plates and silverware to reduce the use of paper or plastic

  • They have replaced older air handlers with more energy efficient units to utilize non-CFC refrigerants

  • They have incorporated Hazardous Waste Minimization procedures in our laboratory operations

  • They have organized a “Green Team” committee that takes action through recycling and reduction of food waste programs, as well as other environmental programs


Company insights

“I never wanted us to operate like the bigger pharma companies. To me, the ideal work environment is one where great minds collaborate to accomplish great things, where employees are as much family as they are colleagues, where nothing is taken at face value and rigorous debate helps push our research to higher levels. Every day, I consider myself incredibly lucky to come in and stand alongside such brilliant minds.” – Stuart W. Peltz, Ph.D., PTC Founder and CEO